AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02688140 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mercaptopurine
Study NCT02688140 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Study NCT04647695 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon beta-1b
Description: a 5-day course of subcutaneous injection of interferon β-1b 2mL (16 million IU) consecutively and IV remdesivir 200mg loading on day 1 followed by remdesivir 100mg daily on day 2 to day 5
Study NCT04647695 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remdesivir
Description: a 5-day course of IV remdesivir 200mg loading on day 1 followed by remdesivir 100mg daily on day 2 to day 5
Study NCT03714256 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Device, patient mobility, powered
Description: Pediatric mobility device
Study NCT03231592 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CSA Group
Description: Already included in the arm descriptions.
Study NCT03231592 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Usual Care Group
Description: Already included in the arm descriptions.
Study NCT01132391 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rectogesic® (glyceryl trinitrate 0.4% ointment)
Description: 375 mg of ointment(1,5 mg of glyceryl trinitrate ) / 12h DURING 6 MONTHS
Study NCT01271595 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: sham acupuncture
Description: 12 sessions of sham acupuncture over 8 weeks
Study NCT01271595 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: sham acupuncture
Description: 12 sessions of sham acupuncture over 8 weeks
Study NCT02591251 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Povidone-iodine solution
Study NCT02245308 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Patches
Description: Nicotine replacement therapy in the form of nicotine patches will be provided to ART group participants beginning on their smoking quit date. Nicotine patches may be provided to control group participants as part of usual care.
Study NCT02245308 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine Patches
Description: Nicotine replacement therapy in the form of nicotine patches will be provided to ART group participants beginning on their smoking quit date. Nicotine patches may be provided to control group participants as part of usual care.
Study NCT02245308 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mobile contingency management (mCM)
Description: Mobile contingency management (mCM) is a behavioral intervention designed to provide positive reinforcement for remaining abstinent from smoking. In this intervention, participants are loaned a smart phone equipped with a videocamera and a carbon monoxide (CO) monitor. Participants are trained to upload videos of themselves taking CO readings. Any time a participant uploads a video recording that suggests abstinence (i.e., low CO reading), he/she will be provided a monetary reward.
Study NCT02245308 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smoking cessation counseling
Description: Smoking cessation counseling is a cognitive-behavioral treatment designed to prepare participants for a quit attempt, and to address relapse when necessary.
Study NCT02245308 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Smoking cessation counseling
Description: Smoking cessation counseling is a cognitive-behavioral treatment designed to prepare participants for a quit attempt, and to address relapse when necessary.
Study NCT02245308 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine rescue method
Description: Nicotine replacement therapy in the form of nicotine gum or lozenges will be provided to ART group participants beginning on their smoking quit date. Nicotine gum or lozenges may be provided to control group participants as part of usual care.
Study NCT02245308 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine rescue method
Description: Nicotine replacement therapy in the form of nicotine gum or lozenges will be provided to ART group participants beginning on their smoking quit date. Nicotine gum or lozenges may be provided to control group participants as part of usual care.
Study NCT02245308 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion
Description: Bupropion SR may be prescribed to medically eligible ART group participants beginning one week prior to quit date. Bupropion may also be prescribed to control group participants as part of usual care.
Study NCT02245308 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupropion
Description: Bupropion SR may be prescribed to medically eligible ART group participants beginning one week prior to quit date. Bupropion may also be prescribed to control group participants as part of usual care.
Study NCT02407704 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venlafaxine XR
Study NCT02407704 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Venlafaxine XR
Study NCT01503372 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib
Description: Adding Pazopanib to a standard chemotherapy consisting of FLO. 800 mg (2x400mg or 4x200mg) Pazopanib per day should be taken orally without food at least one hour before or two hours after a meal. Pazopanib will be given d1-14 each cycle (2 weeks cycles) with 12 cycles of chemotherapy FLO (d 1, each cycle). After 12 cycles chemotherapy FLO will be discontinued and Pazopanib will be given alone until disease progression
Study NCT01503372 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU, Oxaliplatin, Leukovorin (FLO)
Description: Oxaliplatin 85 mg/m2 2h iv Leucovorin 200mg/m2 2h - iv FU 2600mg/m2 24h iv q2w for 12 cycles
Study NCT01503372 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-FU, Oxaliplatin, Leukovorin (FLO)
Description: Oxaliplatin 85 mg/m2 2h iv Leucovorin 200mg/m2 2h - iv FU 2600mg/m2 24h iv q2w for 12 cycles
Study NCT02407704 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise
Study NCT02591251 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal saline solution
Study NCT05012709 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: multisensory stimulation therapy
Description: The intervention group received six 30-minute MST sessions. During MST session, participants can choose their preferred sensory stimuli such as essential oil diffuses, music and so on.
Study NCT02407704 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorazepam
Description: Lorazepam may be used in the study for patients who either are already on this drug or who need it for sleep and/or anxiety. Patients taking another benzodiazepine will be asked to convert from their current benzodiazepine to an equivalent dose of Lorazepam (2mg or less in 24 hours). This will be administered in pill form.
Study NCT02407704 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lorazepam
Description: Lorazepam may be used in the study for patients who either are already on this drug or who need it for sleep and/or anxiety. Patients taking another benzodiazepine will be asked to convert from their current benzodiazepine to an equivalent dose of Lorazepam (2mg or less in 24 hours). This will be administered in pill form.
Study NCT02337257 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol
Description: subjects will receive one pill per day which contains 4000 IU/d for 16 weeks
Study NCT02337257 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: subjects will receive placebo one pill per day for 16 weeks
Study NCT00426907 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Unlimited postoperative weightbearing
Description: Unlimited postoperative weightbearing
Study NCT00426907 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Unlimited postoperative weightbearing
Description: Unlimited postoperative weightbearing
Study NCT01849224 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pelvic and lower extremity exercise
Study NCT01936103 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: standard group
Description: standard statin treatment:Atorvastatin statins 20mg / night .
Study NCT01936103 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intensive group
Description: intensive statin treatment： Admission atorvastatin statins the 80mg, after surgery，atorvastatin 40mg / night，and until 30 days after the operation
Study NCT00312208 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel, doxorubicin, cyclophosphamide
Description: TAC x 6 : Docetaxel 75 mg/m² as 1 hour IV infusion on day 1 every 3 weeks in combination with doxorubicin 50 mg/m² as an IV bolus and cyclophosphamide 500 mg/m2 as IV on day 1 every 3 weeks. Sequence of administration is as follows: doxorubicin followed by cyclophosphamide followed by docetaxel.
Study NCT00312208 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel,doxorubicin, cyclophosphamide
Description: AC x 4: Doxorubicin 60 mg/m² as an IV bolus in combination with cyclophosphamide 600 mg/m² as IV followed by docetaxel 100 mg/m² as 1 hour IV infusion on day 1 every 3 weeks for 4 cycles.
Study NCT03642366 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dornier Aries2 LiST Device + 5mg Tadalafil (1)
Description: Patients will receive shockwave treatments (12 sessions for all subjects, 5000 shockwaves at each session, at energy level 7), three times a week (total of 4 weeks) without treatment interval. Starting at first LiST session and finishing at the final week of LiST sessions, subjects will receive Tadalafil 5mg for 4 weeks daily. Total treatment period = 4 weeks.
Study NCT03642366 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dornier Aries2 LiST Device + 5mg Tadalafil (2)
Description: Patients will receive shockwave treatments (12 sessions for all subjects, 5000 shockwaves at each session, at energy level 7), three times a week (total of 4 weeks) without treatment interval. Starting at first LiST session and finishing at the final week of LiST sessions, subjects will receive Tadalafil 5mg for 4 weeks daily. Total treatment period = 4 weeks.
Study NCT03642366 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham LiST Device + 5mg Tadalafil
Description: Patients will receive sham shockwave treatment (12 sessions for all subjects, 5000 shockwaves at each session, at energy level 7)using a sham probe identical to active probes, three times a week (total of 4 weeks) without treatment interval. Starting at first LiST session and finishing at the final week of LiST sessions, subjects will receive Tadalafil 5mg for 4 weeks daily. Total treatment period = 4 weeks. The IIEF-ED domain will be evaluated at Visit 1 and, consequently, at baseline and all follow up visits together with the SEP diaries.
Study NCT01773993 — intervention group
Intervention type: DRUG
Intervention: Pregabalin
Description: The usual adult dosage for oral use begins at 150 mg/day of pregabalin twice daily, and should be gradually increased to 300 mg/day over 1 week or more and then maintained at 300-450 mg/day as needed. Dosage should be adjusted, depending on age or symptoms. However, the daily maximum dose should not be beyond 450 mg, and should be orally administered twice daily.
Study NCT05340452 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Klaribact 125mg/5ml Suspension
Description: one single 20 mL dose (500mg) of the test drug will be administered to the volunteers
Study NCT05340452 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Klaricid 125mg/5ml Suspension
Description: one single 20 mL dose (500mg) of the Reference drug will be administered to the volunteers
Study NCT01590446 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMN 111
Description: SC injection, Part 1 single dose and Part 2 multiple dose.
Study NCT01590446 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: SC injection, Part 1 single dose and Part 2 multiple dose
Study NCT01373099 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Implantation of a static, non-articulating cement spacer.
Description: After diagnosis of infection and informed consent, patients will be taken to the operating room. After anesthetization, patients will be randomized to either an articulating spacer or static spacer. Randomization will be performed by prepared opaque envelopes administered by a nonparticipant in the study. After a complete debridement of devitalized tissue, explantation of infected components and any associated cement, either an articulating or static spacer will be placed. All spacers will be formed using 3.0 g of Vancomycin and 1.0 g of Tobramycin for each 40 g packet of cement. Static spacers will be hand-made with a rod of antibiotic-impregnated cement and cement beads of sufficient quantity to fill the acetabulum.
Study NCT01373099 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Implantation of an articulating spacer.
Description: After diagnosis of infection and informed consent, patients will be taken to the operating room. After anesthetization, patients will be randomized to either an articulating spacer or static spacer. Randomization will be performed by prepared opaque envelopes administered by a nonparticipant in the study. After a complete debridement of devitalized tissue, explantation of infected components and any associated cement, either an articulating or static spacer will be placed. All spacers will be formed using 3.0 g of Vancomycin and 1.0 g of Tobramycin for each 40 g packet of cement. Articulating spacers will be formed of antibiotic-impregnated cement using the Stage One system (Biomet, Warsaw, IN) sized to fit the endosteal and acetabular bone defect.
Study NCT04173481 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rood's Group
Description: ROOD'S sensory motor training~Brushing \& strokings 3-5 strokings after 30sec, joint compressions and slow stretch 10 rep of 3 sets on alternative days for consecutive 6 weeks CIMT training~Writing, combing hairs and using spoon activity 1 hour training concentrated on affected limb along with restraint of non affected limb by cotton sling under supervision of therapist and 5 hours training in home plan 3 times a week on alternative days for consecutive 6 weeks along with conventional physical therapy.
Study NCT01579058 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bisoprolol
Description: bisoprolol 5mg qd for 4 years
Study NCT01579058 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo for 4 years
Study NCT01709110 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teriparatide
Description: Administered SC
Study NCT01709110 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risedronate
Description: Administered orally
Study NCT01709110 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Teriparatide arm placebo administered orally.~Risedronate arm placebo administered SC.
Study NCT01709110 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Teriparatide arm placebo administered orally.~Risedronate arm placebo administered SC.
Study NCT01709110 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcium
Description: Administered orally
Study NCT01709110 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium
Description: Administered orally
Study NCT01709110 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Description: Administered orally
Study NCT01709110 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Administered orally
Study NCT02789345 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Description: Administered IV
Study NCT02789345 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Necitumumab
Description: Administered IV
Study NCT02789345 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: Administered orally
Study NCT02189044 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Pilates Exercise
Description: The training through the Pilates exercises were performed in eleven weeks. Each class consisted of five exercises lasting 40 minutes each lesson.~During the first four weeks exercises performed were: Cat, Coffee Table, Single legcircle, pelvic movements, contraction of the glutes and closure was performed with posterior chain elongation range.~In the next four weeks began a new series of exercises, which are: Bridge, Side Table, Bridge hip roll with legextension, Abdominal - halfhollup, obliques, and ultimately Stretching - Series of William's.~In the last four weeks of training proposed a new series of exercises involving: Beaststroke, Support heel Bridge - hip roll with leg extension, and Hundred Squats with bat on the wall.
Study NCT02774200 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Apatinib 500 mg, po, qd, continuous medication for a period of eight weeks.
Study NCT04227275 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CART-PSMA-TGFβRDN
Description: Intravenous administration of genetically modified autologous T cells engineered to express a protein capable of recognizing the tumor antigen prostate-specific membrane antigen (PSMA), as well as a dominant negative TGFβ receptor
Study NCT04227275 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Patients will receive cyclophosphamide and fludarabine lymphodepletion chemotherapy followed by the investigational product, CART-PSMA-TGFβRDN genetically modified T cells
Study NCT04227275 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Patients will receive cyclophosphamide and fludarabine lymphodepletion chemotherapy followed by the investigational product, CART-PSMA-TGFβRDN genetically modified T cells
Study NCT04227275 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anakinra
Description: In applicable cohorts, patients will receive anakinra prophylactically starting on the day of administration of investigational product, CART-PSMA-TGFβRDN genetically modified T cells
Study NCT00301392 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: life-style intervention
Description: As the life-style interventions aiming to reduce the major risks of developing diabetes mellitus, instruct the following four items:(1)set diet right, (2)maintain normal weight,(3)improve physical activity,(4)normalize smoking and alcohol drinking.
Study NCT00301392 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Life style interventions plus concomitant use of pitavastatin.
Description: Once-daily dosing of pitavastatin 1 mg(1 tablet of Livalo Tab 1 mg), or 2mg(2 tablets of Livalo Tab 1mg or 1 tablet of Livalo Tab 2mg);Dosing period of pitavastatin should be 60 months.(max.84 months).
Study NCT02465723 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI with IVIM DW-MRI
Study NCT02465723 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood draw
Description: For each patient enrolled, 8-10 mL of whole blood will be collected into glass, anti-coagulant-free tubes and allowed to clot 20-30 minutes.
Study NCT02364115 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiotherapy
Study NCT02480439 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-648 Tablet
Description: Tak-648 tablet
Study NCT02480439 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-648 Oral Solution
Description: TAK-648 oral solution
Study NCT02268084 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic EEG/ECG-guided Resonance Therapy
Description: A coil delivers a pulsed magnetic field to the cortex of the brain
Study NCT02268084 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Sham coil simulates behavior of the intervention magnetic coil without applying the magnetic field
Study NCT04173481 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Physical Therapy Group
Description: Conventional training Proprioceptive neuromuscular facilitations (PNF) Combination of Isotonics technique 10 rep 3 sets 10 sec hold on alternative days for consecutive 6 weeks Stretching's 10 rep 3 sets on alternative days for consecutive 6 weeks Joint approximation 10 rep of 3 sets on alternative days for 6 weeks
Study NCT02095574 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]ABT-199 (GDC-0199)
Description: \[14C\]ABT-199 will be administered as a single oral administration
Study NCT00552916 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Compex Motion Stimulator
Description: 'True' Functional Electrical Stimulation Assisted Walking
Study NCT00552916 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Compex Motion Stimulator
Description: 'False' FES
Study NCT03415217 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Neighbourhood Team Development Program
Description: The Neighbourhood Team Development Program aims to both enhance team development and resident centredness in LTC. The Program has three components, designed to modify the physical environment, the organization and delivery of services, and the alignment of staff members, to function independently and collaboratively in providing resident-centred care.
Study NCT03817307 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: USPIO-enhanced MRI
Description: The USPIO contrast agent will be administered intravenously to the subjects. An MRI scan of the neck region is performed 24-36 hours later to detect lymph node metastases.